| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Actinium Pharmaceuticals Inc. | Iomab-B - (SIERRA) | Acute myeloid leukemia (AML) | Phase 3 | Data Released | Intravenous | Oncology |
| Actinium Pharmaceuticals Inc. | Iomab-B - (SIERRA) | Acute myeloid leukemia (AML) | Phase 3 | Data Released | Intravenous | Oncology |
| Actinium Pharmaceuticals Inc. | Actimab-A | Acute Myeloid Leukemia (AML) | Phase 2 | Intravenous | Oncology | |
| Actuate Therapeutics Inc. | Elraglusib (9-ING-41) Plus Carboplatin | Incurable, recurrent, or metastatic salivary gland carcinoma (SGC) | Phase 2 | Intravenous | Oncology | |
| Actuate Therapeutics Inc. | Elraglusib (9-ING-41) - (ACTUATE-1801) | Pancreatic Cancer (combined with GnP) | Phase 2 | Data Released | Intravenous | Oncology |
| Actuate Therapeutics Inc. | Elraglusib in Combination with FOLFIRINOX and Losartan | Previously Untreated Metastatic Pancreatic Cancer | Phase 2 | Enrollment Conclusion | Intravenous | Oncology |
| Acumen Pharmaceuticals Inc. | ACU193 - (ALTITUDE-AD) | Early Alzheimer's disease | Phase 2 | Data Released | Intravenous | Neurology |
| Acurx Pharmaceuticals Inc. | Ibezapolstat | C. difficile Infection | Phase 3 | Type Meeting | Oral | Antibiotic |